PFIZER INC Cash and Restricted Cash
PFIZER INC (PFE) had Cash and Restricted Cash of $1.03 billion as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.03B.
- 2026-03-29: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.76B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.20B.
- 2025-09-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.39B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-28 | $1.03B 10-Q · filed 2026-08-04 |
| 2026-03-29 | $1.76B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.20B 10-Q · filed 2026-08-04 |
| 2025-09-28 | $1.39B 10-Q · filed 2025-11-04 |
| 2025-06-29 | $1.69B 10-Q · filed 2026-08-04 |
| 2025-03-30 | $1.48B 10-Q · filed 2026-05-05 |
| 2024-12-31 | $1.11B 10-Q · filed 2026-08-04 |
| 2024-09-29 | $1.15B 10-Q · filed 2025-11-04 |
| 2024-06-30 | $1.12B 10-Q · filed 2025-08-05 |
| 2024-03-31 | $780.00M 10-Q · filed 2025-05-05 |
| 2023-12-31 | $2.92B 10-K · filed 2026-02-26 |
| 2023-10-01 | $3.23B 10-Q · filed 2024-11-04 |
| 2023-07-02 | $2.70B 10-Q · filed 2024-08-05 |
| 2023-04-02 | $2.22B 10-Q · filed 2024-05-08 |
| 2022-12-31 | $468.00M 10-K · filed 2026-02-26 |
| 2022-10-02 | $1.34B 10-Q · filed 2023-11-08 |
| 2022-07-03 | $1.82B 10-Q · filed 2023-08-09 |
| 2022-04-03 | $2.51B 10-Q · filed 2023-05-10 |
| 2021-12-31 | $1.98B 10-K · filed 2025-02-27 |
| 2021-10-03 | $2.03B 10-Q · filed 2022-11-09 |
| 2021-07-04 | $2.42B 10-Q · filed 2022-08-10 |
| 2021-04-04 | $1.81B 10-Q · filed 2022-05-11 |
| 2020-12-31 | $1.82B 10-K · filed 2024-02-22 |
| 2020-09-27 | $1.63B 10-Q · filed 2021-11-12 |
| 2020-06-28 | $1.84B 10-Q · filed 2021-08-12 |
| 2020-03-29 | $2.20B 10-Q · filed 2021-05-13 |
| 2019-12-31 | $1.35B 10-K · filed 2023-02-23 |
| 2019-09-29 | $2.85B 10-Q · filed 2020-11-05 |
| 2019-06-30 | $1.84B 10-Q · filed 2020-08-06 |
| 2019-03-31 | $2.02B 10-Q · filed 2020-05-07 |
| 2018-12-31 | $1.23B 10-K · filed 2022-02-24 |
| 2018-09-30 | $3.66B 10-Q · filed 2019-11-07 |
| 2018-07-01 | $2.81B 10-Q · filed 2019-08-08 |
| 2018-04-01 | $2.42B 10-Q · filed 2019-05-09 |
| 2017-12-31 | $1.43B 10-K · filed 2021-02-25 |
| 2017-10-01 | $2.86B 10-Q · filed 2018-11-08 |
| 2017-07-02 | $2.66B 10-Q · filed 2018-08-09 |
| 2017-04-02 | $4.13B 10-Q · filed 2018-05-10 |
| 2016-12-31 | $2.67B 10-K · filed 2020-02-27 |
| 2015-12-31 | $3.71B 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |